Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.68 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 3/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27117910 | 0.94 | GLP1R (0.65) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL22055445 | 0.94 | GLP1R (0.65) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27142852 | 0.94 | GLP1R (0.65) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27109909 | 0.93 | GLP1R (0.69) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL22923670 | 0.92 | GLP1R (0.73) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL15259274 | 0.90 | GLP1R (0.75) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL18354362 | 0.89 | GLP1R (0.70) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL18359104 | 0.89 | GLP1R (0.70) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL14240494 | 0.89 | GLP1R (0.70) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27117453 | 0.88 | GLP1R (0.68) | GLP1RLPAR3LPAR1TLR2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |